Clinical Study

Appropriate Patient Selection in the Management of Common Bile Duct Stones: When Not to Do ERCP

Table 1

Clinical, biochemical, and ultrasound risk features for the presence of CBD stones.

Risk factorOdds ratio95% C.I.SensitivitySpecificity

Clinical11.260.46–3.4542%86%
Biochemical223.93.0–18896%59%
Ultrasound33.031.12–8.1946%88%
Biochemical and/or ultrasound29.33.89–221.296%56%
Biochemical and ultrasound8.883.48–22.6846%96%

1High clinical risk: history of pancreatitis, jaundice, or cholangitis.
2High biochemical risk: raised ALT or ALP or bilirubin.
3High ultrasound risk: dilated CBD >7 mm or visualized CBD stone.